Abstract
Aim: We investigated the diagnostic value of Pentraxin 3 (PTX-3), a marker that increases in vascular and inflammatory pathologies, in patients admitted to hospital with deep vein thrombosis clinic. Materials and Methods: 44 patients admitted to the a tertiary medical faculty hospital and a tertiary training and research hospital, with suspect of deep vein thrombosis included in our study. Patients confirmed to have DVT by doppler ultrasonography named as DVT(+) group, and patients not confirmed to have DVT by doppler ultrasonography named as DVT (-). PTX-3 levels determined in blood samples and compared between these groups. Results: Median levels of D-dimer in DVT(+) group was 3.92 μg/ml (1.57- 6.05), and in DVT (-) group was 1.47 μg/ml (0.97-2.37), and a statistically significant difference was found between these groups (p<0.05). Median levels of Pentraxin-3 in DVT(+) group was 0.42 (0.36-0.49) μg/ml, and in DVT(-) group 0.40 (0.37-0.49) μg/ml, and there was no significant difference found between these groups (p˃0.05). Conclusion: According to our study, PTX-3 is not a suitable diagnostic marker for the diagnosis of deep vein thrombosis. We think that the value of PTX-3 in the diagnosis of deep vein thrombosis now need to be confirmed with broader, controlled studies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
